Clinical Trial

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-01; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2024-02-13
Trial Details
NCT Number NCT05765500
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Prostate Cancer Foundation, Pfizer, Sumitomo Pharma America, Inc.
Conditions Prostate Cancer, Prostatic Neoplasms
Enrollment 110 participants
Start Date 2024-02-12
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30